Clinical Trial Update: TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TACE plus Lenvatinib versus TACE followed by Lenvatinib in hepatocellular carcinoma (liver cancer). Status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• TACE

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN